Clot-Busting Treatment Improves Bleeding Strok... ( Low dose tPA dissolved masses 2 to 3 ...)

Clot-Busting Treatment Improves Bleeding Stroke Outcomes

Date:5/14/2008

Low dose tPA dissolved masses 2 to 3 times faster, dramatically boosting survival

WEDNESDAY, May 14 (HealthDay News) -- Researchers report they have dramatically increased the survival rate for people with strokes caused by bleeding within the brain by fine-tuning the dosage and timing for administering the clot-busting drug tissue plasminogen activator (tPA).

"We've gone from what's usually an 80 percent death rate in patients with this condition to an 80 percent survival rate," study leader Dr. Daniel Hanley, a professor of neurology at the Johns Hopkins University School of Medicine, said in a prepared statement.

This new treatment protocol for intracerebral hemorrhage (ICH) was developed through a multi-center study and reported this week at the European Stroke Conference, in Nice, France.

ICH causes blood to clot inside the brain's interior cavities, building up pressure within the brain. The higher pressure, along with inflammation caused by chemicals in the trapped blood, can irreversibly damage the brain, usually leading to death or extreme disability. No treatment existed for this until recently, Hanley said.

High doses (80 milligrams to 100 milligrams) of tPA have proven effective at breaking up clots in conditions such as heart attacks and other types of strokes, but there was concern that such levels of the drug may cause excessive bleeding in ICH patients. Previous studies showed that giving tPA to ICH patients hadn't significantly increased bleeding or death, so Hanley and his colleagues tested low doses to try to find the safest and most effective treatment regimen possible.

The researchers recruited 52 patients from across the United States, Canada, Great Britain and Germany who were recently diagnosed with ICH. Using the same catheter the patients had received inside the brain to release the trapped blood (the usual treatment for ICH), the researchers flooded tPA directly
'/>"/>

0

GOOD

Page: 1 2
Related medicine news :

1. Researchers fine-tune clot-busting treatment for bleeding in brain
2. Clot-Busting Drug Offers New Approach to DVT
3. FDA Approves AstraZenecas Seroquel(R) for Maintenance Treatment in Bipolar Disorder
4. Study Suggests Green Tea May Support the Medical Treatment of Stomach and Colon Cancer
5. Blood-Thinner No Help for Dialysis Treatment
6. Simvastatin Leads Pfizers Lipitor in Second-Line Patient Share for the Treatment of Dyslipidemia
7. FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
8. Medical Research Should Include More Women Participants and Examine the Role of Gender in Disease Incidence and Treatment
9. Homeless youth need more than treatment for substance abuse, study says
10. Newer Prostate Cancer Treatment Similar to Traditional Surgery
11. Improving anxiety treatment through the help of brain imaging: A potential future treatment strategy

Post Your Comments:

(Date:5/21/2013)... May 21, 2013 ContinuCare Home Health, ... Department of Aging and Disability Services. After completing a ... interviews, ContinuCare Home Health was found to have ... is part of the Department of Aging and Disability ... and disability services, supports and opportunities that are ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 Artisan ... EB-5 Investment Summit: Dealmakers Conference in Long Beach, ... will focus on exploring alternative finance through EB-5 ... latest market, legal and economic information, and updates ... legal professionals within the EB-5 industry. , ...

(Date:5/21/2013)... May 21, 2013 According to a May ... the Use of Botox,” Botox injections have become ... approval in 2002 (Go to goo.gl/8iYbD). Although it is mostly ... with men. The injection makes facial wrinkles less visible by ... last for about three months. This means that people who ...

(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve ... the Creative Corridor region, is releasing results for its ... on Thursday, May 23rd at 10:30 a.m. The ... , The survey is a critical component to ... attract, nurture and retain people of diverse backgrounds, cultures ...

(Date:5/21/2013)... (May 21, 2013) A paper recently published in ... co-written by physicians and scientists at the University of ... risk factor for pulmonary fibrosis can be used to ... , Researchers looked at a fairly common variant of ... component of the mucous produced by the bronchial tubes. ...

Breaking Medicine News(10 mins):Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2 Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2 Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2 Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2 Health News:Researchers find genetic risk factor for pulmonary fibrosis 2

[0] ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services [0] Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California [0] Botox – Is the World’s Most Popular Cosmetic Procedure Safe?[0] Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m.[0] Researchers find genetic risk factor for pulmonary fibrosis

... Boston Scientific,Corporation (NYSE: BSX ) today announced ... ALTRUA(TM) family of pacemakers. ALTRUA is Boston,Scientific,s most ... small size and battery longevity. It is the ... in which the,heart beats too slowly -- usually ...

... Inc.,("GNC" or the "Company"), the largest global specialty ... for the first,quarter ended March 31, 2008., ... of GNC Parent LLC,which was acquired on March ... and Ontario Teachers, Pension Plan Board ("Teachers"). As ...

... Alimera Sciences Inc., a privately held,ophthalmic pharmaceutical ... pilot study to assess the safety and efficacy ... Genentech) in patients,with exudative age-related macular degeneration (wet ... performed under an investigator,sponsored IND, will compare two ...

... Market Share in Europe and Canada; ... LAVAL, QC, May 8 /PRNewswire-FirstCall/ - Labopharm Inc. ... first quarter ended March,31, 2008. All figures are in ... to make strong progress in the global,commercialization of our ...

... Appeals for More than $8 million for medicines and other lifesaving ... ... As the death toll from,Cyclone Nargis climbs steeply, UNICEF is gravely ... sanitary conditions,could significantly increase the death toll among children and other,vulnerable populations, ...

... Inc. ("Holdings",or the "Company"), the parent company of ... largest cancer services companies, reported revenue of,$810.6 million, ... flow of,$50.9 million for the quarter ended March ... those of US Oncology, its wholly-owned,subsidiary, through which ...

Boston Scientific Announces FDA Approval of New Family of Advanced Pacemakers General Nutrition Centers, Inc. Reports First Quarter 2008 Financial Results Pilot Study to Assess Safety and Efficacy of Medidur(TM) FA in AMD Patients Treated With Lucentis(R)Labopharm Reports Results for First Quarter Fiscal 2008 Myanmar Cyclone a Children's Catastrophe - UNICEF US Oncology Reports First Quarter 2008 Results

(Date:5/21/2013)... N.Y., May 21, 2013 Lakeland Industries, Inc. ... manufacturer of industrial protective clothing for industry, municipalities, ... and local levels, today announced that the Company ... a Senior Credit Facility subject to certain terms ... this financing. However, no assurances can be given ...

(Date:5/21/2013)... CEO of Mammotome, a division of Devicor Medical Products, has ... Cincinnati chapter of the Association for Corporate Growth ... who is also a breast cancer survivor, led the purchase ... 2010. Daulton will be presented with the award at the ... May 22. The ACG Deal Maker Awards program ...

(Date:5/21/2013)... May 21, 2013 Kepner-Tregoe (KT), the ... that 13-year veteran Chris Geraghty ... experience includes more than 20 years serving the ... manufacturing organizations. He succeeds Ray Baxter ... Kepner-Tregoe,s Chairman of the Board and CEO. ...

[0] Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results [0] Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year [0] Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer

... ZURICH, July 16 An innovative treatment ... patients has received a second,orphan drug designation in ... was,granted. The recent designation relates to Burkholderia cepacia ... patients. For Axentis,Pharma AG of Zurich, Switzerland, both ...

... , BOSTON and EDISON, N.J., July ... with edoxaban(2) - an investigational oral Factor Xa inhibitor - ... receiving edoxaban once daily (QD) experienced fewer bleeding events than ... that bleeding associated with edoxaban is most closely correlated with ...

Cached Medicine Technology:Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 2 Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 3 Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 2 Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 3 Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 4 Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 5

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

Medicine Products:

Pelvic Washing for Cytology PBG, Urine Quantitative Parvovirus B19 Antibody, IgM Parvovirus B 19, by PCR, Bone Marrow